28th January 2025
Latest news
Find all of our recent press releases, stay updated with the latest news and be informed about upcoming events where Curium will be attending.
Please direct any media inquiries to: communications@curiumpharma.com
10th September 2024
Curium Announces Pylclari® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer – is now available in Spain
17th June 2024
Curium Continues to Make Strong Progress in European roll-out of Pylclari® – ¹⁸F-PSMA PET Diagnostics of Patients With Prostate Cancer
30th May 2024
Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
6th May 2024
Curium announces first commercial doses in Germany of PYLCLARI® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer
23rd April 2024
Curium Enrolls First Prostate Cancer Patients in its Phase 3 SOLAR Trials
8th April 2024
Curium plans to significantly expand Lutetium-177 capacity and PET footprint with agreement to acquire Eczacibaşi-Monrol
19th March 2024
Curium announces first commercial doses in the Netherlands of PYLCLARI® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer
7th March 2024
Curium announces first commercial doses in Italy of PYLCLARI® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer
21st February 2024